
Inscripta: MAD7 CRISPR enzyme widely adopted in first year of availability
BOULDER -- Inscripta , a gene-editing technology company, today announced MAD7, its proprietary CRISPR enzyme, has achieved wide adoption by academic, commercial, and government researchers in... Read More
Thursday December 20, 2018 0 comments

Inscripta announces two major milestones
BOULDER -- Inscripta , a gene-editing technology company, announced two significant milestones. First, the USPTO granted Inscripta its first patent covering systems using MAD7, the... Read More
Friday July 13, 2018 0 comments